Mechanisms and interventions in peritoneal fibrosis

Clinical and Experimental Nephrology

Volumn 16, Issue 1, 2012, Pages 109-114

  Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal model; Peritoneal dialysis; Peritoneal fibrosis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DECORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EMODIN; ENALAPRIL; LOSARTAN; PENTOXIFYLLINE; PERITONEAL DIALYSIS FLUID; PYRIDOXAMINE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN; VASCULOTROPIN ANTIBODY;

CELL TRANSPLANTATION; CHRONIC INFLAMMATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MESOTHELIUM CELL; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTHRANILIC ACIDS; EPITHELIAL CELLS; EPITHELIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PHENYL ETHERS; PYRIDOXAMINE; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858288140     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0533-y     Document Type: Review

References (44)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470-9. (Pubitemid 34106290)
2. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int. 2001;59(Suppl 78):S42-7. (Pubitemid 32144068)
3. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transpl. 2002;17(Suppl 3):12-5. (Pubitemid 34450111)
4. Naiki Y, Maeda Y, Matsuo K, Yonekawa S, Sakaguchi M, Iwamoto I, et al. Involvement of TGF-β signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol. 2003;16:95-102.
5. Osada S, Hamada C, Shimaoka T, Hayashi K, Horikoshi S, Tomino Y. Alteration in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transpl. 2009;24:3504-12.
6. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-b1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int. 1999;19: 221-30. (Pubitemid 30015544)
7. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol. 2001;12:2029-39. (Pubitemid 32880339)
8. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol. 2001;12: 2434-41. (Pubitemid 33021121)
9. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med. 2001;138: 59-68. (Pubitemid 32589202)
10. Honda K, Nitta K, Horita S, Yamura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transpl. 1999;14:1541-9. (Pubitemid 29241752)
11. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol. 2001;12:2146-57. (Pubitemid 32880352)
12. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209-20. (Pubitemid 34778983)
13. Rougier JP, Guia S, Hagege J, Nguyen G, Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-β1. Kidney Int. 1998;54:87-98. (Pubitemid 28288023)
14. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab. 2000;71:276-92.
15. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005;25:38-47. (Pubitemid 40378496)
16. Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 2005;67:1126-35. (Pubitemid 41623339)
17. Yung S, Liu ZH, Lai KN, Li LS, Chan TM. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor β1 and fibronectin by human peritoneal mesothelial cells. Perit Dial Int. 2001;21(Suppl 3):S41-7.
18. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int. 2003;64:519-33. (Pubitemid 36871923)
19. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol. 2002;13:721-8. (Pubitemid 34183938)
20. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int. 2004;66:408-18. (Pubitemid 38870119)
21. Bajo MA, Selgas R, Castro MA, del Peso G, Diaz C, Sanchez-Tomero JA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int. 2000;20:742-7. (Pubitemid 32186003)
22. Le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int. 2005;25(Suppl 3):S64-8.
23. Fukuyama J, Ichikawa K, Miyazawa K, Hamano S, Shibata N, Ujiie A. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol. 1996;70:321-7.
24. Fukuyama J, Ichikawa K, Hamano S, Shibata N. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol. 1996;318: 327-32. (Pubitemid 27046275)
25. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int. 2005;25: 483-91. (Pubitemid 41448405)
26. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int. 2001;21:219-24. (Pubitemid 32447809)
27. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs. 2005;28:156-63. (Pubitemid 40485215)
28. Giri SN, Biring I, Nguyen T, Wang O, Hyde DM. Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide. 2002;7:109-18. (Pubitemid 35177002)
29. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transpl. 2005;20:2783-92. (Pubitemid 41672280)
30. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism. 2007;56:160-7. (Pubitemid 46074060)
31. Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M, et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int. 2005;68:1326-36. (Pubitemid 43246454)
32. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ. Pentoxifylline modulates intracellular signalling of TGF-β in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transpl. 2003;18:670-6.
33. Fang CC, Yen CJ, Chen YM, Chu TS, Lin MT, Yang JY, et al. Diltiazem suppresses collagen synthesis and IL-1β-induced TGF-β1 production on human peritoneal mesothelial cells. Nephrol Dial Transpl. 2006;21:1340-7.
34. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGF-β-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int. 2001;60: 1249-57.
35. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65: 1927-36. (Pubitemid 38591045)
36. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int. 2004;66:1677-85. (Pubitemid 39298405)
37. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transpl. 2007;22:2838-48. (Pubitemid 350093438)
38. Di Paolo N, Sacchi G, Vanni L, Corazzi S, Terrana B, Rossi P, et al. Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron. 1991;57:323-31.
39. Hekking LH, Harvey VS, Havenith CE, van den Born J, Beelen RH, Jackman RW, et al. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis. Perit Dial Int. 2003;23:323-30. (Pubitemid 37038728)
40. Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther. 1995;2:402-10.
41. Hekking LH, Zweers MM, Keuning ED, Driesprong BA, de Waart DR, Beelen RH, et al. Apparent successful mesothelial cell transplantation hampered by peritoneal activation. Kidney Int. 2005;68:2362-7. (Pubitemid 43117816)
42. Sekiguchi et al. Roles of bone marrow-derived cells in development of morphological alterations in the peritoneum presented at the 11th Congress of the International Society for Peritoneal Dialysis, 25-26 August 2006, Hong Kong (submitted).
43. Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Intern. 2007;27(Suppl 2):582-6.
44. Hotta Y, Kaneko K, Inuma J, Inami Y, Aruga S, Shimaoka T, Sekiguchi Y, Io H, Hamada C, Obinata M, Ueda M, Tomino Y. Establishment of a peritoneal mesothelial cell line from a transgenic rat harbouring the temperature-sensitive simian virus 40 large T-antigen gene. Nephrol Dial Transpl. 2010;25:1825-32.